Key Points
- CFO James Budge sold 44,589 shares at an average price of $47.47 for total proceeds of $2,116,639.83, reducing his stake by 8.5% to 479,878 shares valued at about $22.78 million.
- Hinge Health beat quarterly expectations with EPS of ($0.02) vs. consensus ($0.20) miss and reported revenue of $154.21 million (up 53.3% year‑over‑year), topping the $142.44 million estimate.
- The board approved a $250 million share buyback (up to 7.2% of shares), while analysts’ consensus is a "Moderate Buy" with an average price target near $59.93.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CFO James Budge sold 44,589 shares of the company's stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $47.47, for a total value of $2,116,639.83. Following the completion of the transaction, the chief financial officer owned 479,878 shares of the company's stock, valued at $22,779,808.66. The trade was a 8.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Hinge Health Stock Performance
HNGE opened at $48.27 on Wednesday. The business's fifty day simple moving average is $49.26. Hinge Health Inc. has a fifty-two week low of $33.42 and a fifty-two week high of $62.18.
Hinge Health (NYSE:HNGE - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.18. The business had revenue of $154.21 million for the quarter, compared to the consensus estimate of $142.44 million. The firm's revenue for the quarter was up 53.3% on a year-over-year basis. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.
Hinge Health declared that its Board of Directors has approved a share repurchase program on Wednesday, November 12th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to buy up to 7.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on HNGE shares. Bank of America upped their price objective on Hinge Health from $42.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Needham & Company LLC boosted their price target on Hinge Health from $47.00 to $59.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Robert W. Baird started coverage on Hinge Health in a research report on Friday, September 5th. They issued a "neutral" rating and a $56.00 price target on the stock. Baird R W upgraded Hinge Health to a "hold" rating in a research note on Friday, September 5th. Finally, Piper Sandler reissued an "overweight" rating and set a $71.00 price objective (up from $70.00) on shares of Hinge Health in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $59.93.
Get Our Latest Report on HNGE
Institutional Investors Weigh In On Hinge Health
A number of large investors have recently bought and sold shares of the business. BIT Capital GmbH raised its position in Hinge Health by 144.6% in the 3rd quarter. BIT Capital GmbH now owns 1,849,524 shares of the company's stock valued at $90,775,000 after purchasing an additional 1,093,320 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Hinge Health by 22.6% during the third quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company's stock worth $60,753,000 after purchasing an additional 228,234 shares during the last quarter. Bamco Inc. NY acquired a new stake in shares of Hinge Health in the second quarter valued at $48,943,000. Braidwell LP acquired a new stake in shares of Hinge Health in the third quarter valued at $44,686,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Hinge Health in the second quarter valued at about $43,840,000.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
